Its a breakthrough in that its a simple oral medication, Eli Lilly CEO Dave Ricks said in an interview
This guarantees you receive a high-quality peptide therapy designed for optimal results and safety
Long-term effects, potential drug interactions, and effects in specific populations including pregnant women, children, and those with certain medical conditions have not been studied
The structural modifications in IGF-1 LR3 may have also contributed to the increased affinity of the peptide towards the IGF-1 receptors
Transdermal-specific considerations for patches would include: Local skin reactions (erythema, itching, irritation at application site) Contact dermatitis from adhesive components or penetration enhancers Skin integrity concerns requiring regular site rotation Patient safety advice for anyone using GLP-1 therapy includes: Report persistent severe abdominal pain (potential pancreatitis) Monitor for signs of gallbladder problems (right upper quadrant pain, particularly after meals) Maintain adequate hydration, especially if experiencing vomiting or diarrhoea Contact your GP if side effects are severe, persistent, or concerning Report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) Regarding pregnancy and breastfeeding, advice varies by product
The lack of FDA approval also means that definitive safety and efficacy trials are still forthcoming
